Cargando…

Long-term Effects of Lifestyle Intervention or Metformin on Diabetes Development and Microvascular Complications: the DPP Outcomes Study

BACKGROUND: The worldwide epidemic of type 2 diabetes requires effective prevention. We determined the long-term extent of beneficial effects of lifestyle intervention and metformin on diabetes prevention, originally demonstrated during the 3-year Diabetes Prevention Program (DPP), and whether diabe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nathan, D. M., Barrett-Connor, E., Crandall, J.P., Edelstein, S. L., Goldberg, R.B., Horton, E. S., Knowler, W.C., Mather, K. J., Orchard, T. J., Pi-Sunyer, X., Schade, D., Temprosa, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623946/ https://www.ncbi.nlm.nih.gov/pubmed/26377054 http://dx.doi.org/10.1016/S2213-8587(15)00291-0

Ejemplares similares

Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study
por: Lee, Christine G., et al.
Publicado: (2021)

Lifestyle and Metformin Interventions Have a Durable Effect to Lower CRP and tPA Levels in the Diabetes Prevention Program Except in Those Who Develop Diabetes
por: Goldberg, Ronald B., et al.
Publicado: (2014)

Erratum. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. Diabetes Care 2017;40:1668–1677
por: Herman, William H., et al.
Publicado: (2018)

Erratum. Impact of lifestyle and metformin interventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation. Diabetes Care 2017;40:1668—1677
por: Herman, William H., et al.
Publicado: (2019)

Effect of Progression From Impaired Glucose Tolerance to Diabetes on Cardiovascular Risk Factors and Its Amelioration by Lifestyle and Metformin Intervention: The Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group
por: Goldberg, Ronald B., et al.
Publicado: (2009)

Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study
por: Luchsinger, José A., et al.
Publicado: (2017)

Predictive utilities of lipid traits, lipoprotein subfractions and other risk factors for incident diabetes: a machine learning approach in the Diabetes Prevention Program
por: Varga, Tibor V, et al.
Publicado: (2021)

Statin use and risk of developing diabetes: results from the Diabetes Prevention Program
por: Crandall, Jill P, et al.
Publicado: (2017)

Regression From Prediabetes to Normal Glucose Regulation Is Associated With Reduction in Cardiovascular Risk: Results From the Diabetes Prevention Program Outcomes Study
por: Perreault, Leigh, et al.
Publicado: (2014)

Comparison of ETDRS 7-Field to 4-Widefield Digital Imaging in the Evaluation of Diabetic Retinopathy Severity
por: Blodi, Barbara A., et al.
Publicado: (2022)

The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention: An intent-to-treat analysis of the DPP/DPPOS
Publicado: (2012)

The C Allele of ATM rs11212617 Does Not Associate With Metformin Response in the Diabetes Prevention Program
por: Florez, Jose C., et al.
Publicado: (2012)

Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome
por: Jahn, Linda A., et al.
Publicado: (2022)

Assessment of Metformin as an Additional Treatment to Therapeutic Lifestyle Changes in Pediatric Patients with Metabolic Syndrome
por: Raub, Rebecca M., et al.
Publicado: (2012)

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
por: Ahrén, Bo
Publicado: (2008)

Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program
por: Aroda, Vanita R, et al.
Publicado: (2020)

The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012;35:723–730
Publicado: (2013)

Hepatic Fat in Participants With and Without Incident Diabetes in the Diabetes Prevention Program Outcome Study
por: Goldberg, Ronald B, et al.
Publicado: (2021)

Metformin as a promising target for DPP4 expression: computational modeling and experimental validation
por: El-Arabey, Amr Ahmed, et al.
Publicado: (2023)

Sex Differences in Diabetes Risk and the Effect of Intensive Lifestyle Modification in the Diabetes Prevention Program
por: Perreault, Leigh, et al.
Publicado: (2008)

ODP173 Control of Alpelisib-Induced Hyperglycemia With DPP4- Inhibitors as add on to Metformin and Insulin
por: Hee, Nicholas Ken Yoong, et al.
Publicado: (2022)

Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin Treatment: The Diabetes Prevention Program
por: Pollin, Toni I., et al.
Publicado: (2012)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

Genetic Risk of Progression to Type 2 Diabetes and Response to Intensive Lifestyle or Metformin in Prediabetic Women With and Without a History of Gestational Diabetes Mellitus
por: Sullivan, Shannon D., et al.
Publicado: (2014)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Pretreatment, Psychological, and Behavioral Predictors of Weight Outcomes Among Lifestyle Intervention Participants in the Diabetes Prevention Program (DPP)
por: Delahanty, Linda M., et al.
Publicado: (2013)

Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program
por: Jablonski, Kathleen A., et al.
Publicado: (2010)

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
por: Goldenberg, Ronald, et al.
Publicado: (2017)

Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY
Publicado: (2013)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Genetic Predictors of Weight Loss and Weight Regain After Intensive Lifestyle Modification, Metformin Treatment, or Standard Care in the Diabetes Prevention Program
por: Delahanty, Linda M., et al.
Publicado: (2012)

Metformin and sulodexide restore cardiac microvascular perfusion capacity in diet-induced obese rats
por: van Haare, Judith, et al.
Publicado: (2017)

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)

Diet quality, weight loss, and diabetes incidence in the Diabetes Prevention Program (DPP)
por: Allaire, Benjamin T., et al.
Publicado: (2020)

Correction to: Metformin and sulodexide restore cardiac microvascular perfusion capacity in diet‑induced obese rats
por: van Haare, Judith, et al.
Publicado: (2021)

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
por: Baggio, Laurie L., et al.
Publicado: (2020)

Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice
por: Bazo-Alvarez, Juan Carlos, et al.
Publicado: (2021)

Correction: Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n27gqorc7uin1j6jksagetotvk